Cargando…

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

BACKGROUND: A reduced amyloid-β (Aβ)42/40 peptide ratio in blood plasma represents a peripheral biomarker of the cerebral amyloid pathology observed in Alzheimer’s disease brains. The magnitude of the measurable effect in plasma is smaller than in cerebrospinal fluid, presumably due to dilution by A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klafki, Hans-Wolfgang, Morgado, Barbara, Wirths, Oliver, Jahn, Olaf, Bauer, Chris, Esselmann, Hermann, Schuchhardt, Johannes, Wiltfang, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719149/ https://www.ncbi.nlm.nih.gov/pubmed/36461122 http://dx.doi.org/10.1186/s12987-022-00390-4

Ejemplares similares

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
por: Shahpasand-Kroner, Hedieh, et al.
Publicado: (2018)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

X-ray diffraction and electron microscopy data for amyloid formation of Aβ40 and Aβ42
por: Selivanova, Olga M., et al.
Publicado: (2016)

Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
por: Baldassarre, Maurizio, et al.
Publicado: (2017)

Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
por: Braun, Gabriel A., et al.
Publicado: (2022)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Matrix Development for the Detection of Phosphorylated Amyloid-β Peptides by MALDI-TOF-MS
por: Liepold, Thomas, et al.
Publicado: (2023)

Aggregation States of Aβ(1–40), Aβ(1–42) and Aβp(3–42) Amyloid Beta Peptides: A SANS Study
por: Festa, Giulia, et al.
Publicado: (2019)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation
por: Klafki, Hans-W., et al.
Publicado: (2022)

Complete aggregation pathway of amyloid β (1-40) and (1-42) resolved on an atomically clean interface
por: Nirmalraj, Peter Niraj, et al.
Publicado: (2020)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
por: Hu, Xiaoyan, et al.
Publicado: (2014)

Allosteric Modulation of PS1/γ-Secretase Conformation Correlates with Amyloid β(42/40) Ratio
por: Uemura, Kengo, et al.
Publicado: (2009)

The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
por: Amft, Michaela, et al.
Publicado: (2022)

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Human platelets release amyloid peptides β(1-40) and β(1-42) in response to hemostatic, immune, and hypoxic stimuli
por: Wolska, Nina, et al.
Publicado: (2023)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Differentiating Aβ40 and Aβ42 in amyloid plaques with a small molecule fluorescence probe
por: Yang, Jing, et al.
Publicado: (2020)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Prognostic Role of CSF β-amyloid 1–42/1–40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis
por: Colletti, Tiziana, et al.
Publicado: (2021)

Dynamic Blood Concentrations of Aβ(1–40) and Aβ(1–42) in Alzheimer’s Disease
por: Yang, Yuan-Han, et al.
Publicado: (2020)

Development and Technical Validation of an Immunoassay for the Detection of APP(669–711) (Aβ(−3–40)) in Biological Samples
por: Klafki, Hans W., et al.
Publicado: (2020)

The HSP40 chaperone Ydj1 drives amyloid beta 42 toxicity
por: Ring, Julia, et al.
Publicado: (2022)

Assessment of Plasma Amyloid-β(42/40) and Cognitive Decline Among Community-Dwelling Older Adults
por: Giudici, Kelly Virecoulon, et al.
Publicado: (2020)

Enhanced Aβ(1–40) Production in Endothelial Cells Stimulated with Fibrillar Aβ(1–42)
por: Rajadas, Jayakumar, et al.
Publicado: (2013)

Different Aggregation Pathways and Structures for Aβ40 and Aβ42 Peptides
por: Wang, Li, et al.
Publicado: (2021)

Accurate characterization of β-amyloid (Aβ40, Aβ42) standards using species-specific isotope dilution by means of HPLC-ICP-MS/MS
por: Schaier, Martin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1qb7ja9l1crcu1qbr5vtuar0gv